01—Abstract
Summary
Summary of the 8-K filed October 30, 2025. Cited figures are marked; the original filing is the authoritative source.
Stryker reported third quarter 2025 results on October 30, 2025 that beat on the top line and showed strong margin expansion, though reported earnings were roughly flat.
Net sales rose 10.3% to $6.06 billiona (9.5% organic), led by MedSurg and Neurotechnology, which grew 14.4% reported and 8.4% organic, helped by the Inari acquisition. Orthopaedics grew 3.9% reported but 11.4% organic, excluding the divested Spinal implant business. Reported operating margin was 18.7%, down from 19.7% a year earlier, because of acquisition-related charges, amortization of intangibles, and impairments.
Adjusted operating margin expanded 90 bps to 25.6%, and adjusted EPS rose 11.1% to $3.19b, while reported diluted EPS increased only 2.8% to $2.22. Management raised full-year 2025 guidance, now expecting organic sales growth of 9.8% to 10.2% and adjusted diluted EPS of $13.50 to $13.60. The guidance includes a modestly favorable pricing impact and a slightly positive FX effect if rates hold.
The balance sheet shows the cost of the Inari deal: goodwill and intangibles rose to $25.1 billionc from $20.3 billion, long-term debt increased to $14.8 billion from $12.2 billion, and nine-month acquisition spending was $4.95 billion. Nine-month reported net earnings declined 2.0% and operating income fell 0.7%, so investors will weigh the strength of adjusted results against the lower GAAP profitability and higher leverage.
02—Key points
Key Highlights
- Net sales up 10.3% to $6.06B (9.5% organic); MedSurg and Neurotechnology +14.4% reported, +8.4% organic, with Vascular up 59.6% in the quarter
- Orthopaedics organic growth of 11.4% (12.5% reported excluding divested Spinal Implants), offset by an 8.3% drag from the Spinal divestiture
- Adjusted operating margin expanded 90 bps to 25.6%; adjusted gross margin 65.0% versus 64.5% a year ago
- Reported diluted EPS up only 2.8% to $2.22 because of amortization ($189M), impairments ($73M), and acquisition-related costs; adjusted EPS up 11.1% to $3.19
- Full-year 2025 guidance raised: organic growth 9.8%–10.2% and adjusted EPS $13.50–$13.60
- Balance sheet is more levered after acquisitions: goodwill and intangibles up to $25.1B, long-term debt up to $14.8B, and nine-month acquisition spend of $4.95B
- Nine-month reported net earnings fell 2.0% to $2.40B and operating income fell 0.7%, with a $139M stock compensation payment on change in control among the drivers
03—Questions
Frequently Asked Questions
Why did reported EPS grow only 2.8% when adjusted EPS grew 11.1%?
The gap comes from non-GAAP adjustments of about $0.97 per share in the quarter. The largest items are amortization of purchased intangibles from recent acquisitions ($0.39 per share), goodwill and other impairments ($0.16), a tax item, and acquisition and integration costs such as inventory step-up. The company treats these as non-recurring or non-operating, but investors should note that amortization and impairments recur in some form.
What is driving the strong MedSurg and Neurotechnology growth?
Vascular sales jumped 59.6% reported and 58.9% in constant currency, largely from the Inari acquisition. Neuro Cranial grew 17.6% and Instruments grew 11.9%. Organic MedSurg growth of 8.4% (7.6% volume) shows the core business also expanded, though the reported figure is inflated by acquisitions.
Is the Orthopaedics business healthy after the Spinal divestiture?
Yes, on an underlying basis. Excluding the divested Spinal Implants business, Orthopaedics grew 12.5% reported and 11.7% in constant currency, and organic growth was 11.4%. Trauma and Extremities (+13.0%) and Knees (+10.2%) led, while Spinal Implants fell 96.7%. The divestiture removes a shrinking, lower-margin revenue stream from the reported total.
What does the raised 2025 guidance imply for investors?
Management raised organic sales growth to 9.8%–10.2% and adjusted EPS to $13.50–$13.60. The company also expects modestly favorable pricing and a slightly positive FX impact if current rates hold. Guidance excludes acquisition, divestiture, and special-charge effects that are not predictable, so reported GAAP EPS could differ materially from the adjusted outlook.
How did the Inari acquisition affect Stryker's balance sheet and cash flow?
The acquisition is the main reason for the balance sheet change. Goodwill and other intangibles rose about $4.9 billion, to $25.1 billion, and long-term debt rose $2.7 billion, to $14.8 billion. Nine-month acquisition spending was $4.95 billion against $2.90 billion of operating cash flow. Cash fell to $3.26 billion from $3.65 billion, and the company paid $963 million in dividends. Leverage and future amortization are therefore higher, which investors should weigh against the growth contribution.
04—Continue